IONTAS Ltd. has entered a collaboration with Adaptate Biotherapeutics, a developer of antibody-based therapeutics for modulation of gamma delta T-cells, to generate and optimize antibodies for novel immuno-oncology targets, including IONTAS’ Mammalian Display technology to select antibodies with optimal biophysical properties.   IONTAS’ technology enables the construction of large libraries of stable cell lines displaying human antibodies on their surface. The technology also addresses “develo...